Thymosin beta-4 (Tβ4) is an ubiquitous multi-functional regenerative peptide, related to many critical biological processes, with a dynamic and flexible conformation which may influence its functions and its subcellular distribution. For these reasons, the intracellular localization and trafficking of Tβ4 is still not completely defined and is still under investigation in in vivo as well as in vitro studies. In the current study we used HepG2 cells, a human hepatoma cell line; cells growing in normal conditions with fetal bovine serum expressed high levels of Tβ4, restricted to the cytoplasm until 72 h. At 84 h, a diffuse Tβ4 cytoplasmic immunostaining shifted to a focal perinuclear and nuclear reactivity. In the absence of serum, nuclear reactivity was localized in small granules, evenly dispersed throughout the entire nuclear envelop, and was observed as earlier as at 48 h. Cytoplasmic immunostaining for Tβ4 in HepG2 cells under starvation appeared significantly lower at 48 h and decreased progressively at 72 and at 84 h. At these time points, the decrease in cytoplasmic staining was associated with a progressive increase in nuclear reactivity, suggesting a possible translocation of the peptide from the cytoplasm to the nuclear membrane. The normal immunocytochemical pattern was restored when culture cells submitted to starvation for 84 h received a new complete medium for 48 h. Mass spectrometry analysis, performed on the nuclear and cytosolic fractions of HepG2 growing with and without serum, showed that Tβ4 was detectable only in the cytosolic and not in the intranuclear fraction. These data suggest that Tβ4 is able to translocate from different cytoplasmic domains to the nuclear membrane and back, based on different stress conditions within the cell. The punctuate pattern of nuclear Tβ4 immunostaining associated with Tβ4 absence in the nucleoplasm suggest that this peptide might be localized in the nuclear pores, where it could regulate the pore permeability.
References
[1]
Goldstein AL, Slater FD, White A (1966) Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci USA 56: 1010–1007.
[2]
Low TL, Hu SK, Goldstein AL (1981) Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci USA 78: 1162–1166.
[3]
Ballweber E, Hannappel E, Huff T, Stephan H, Haener M, et al. (2002) Polymerization of chemically cross-linked actin:thymosin beta(4) complex to filamentous actin: alteration in helical parameters and visualization of thymosin beta(4) binding on F-actin. J Mol Biol 315: 613–625.
[4]
Sanders MC, Goldstein AL, Wang YL (1992) Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proc Natl Acad Sci USA 89: 4678–4682.
[5]
Goldstein AL, Hannappel E, Sosne G, Kleinman HK (2012) Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 12: 37–51.
[6]
Koutrafouri V, Leondiadis L, Avgoustakis K, Livaniou E, Czarnecki J, et al. (2001) Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model. Biochim Biophys Acta 1568: 60–66.
Badamchian M, Fagarasan MO, Danner RL, Suffredini AF, Damavandy H, et al. (2003) Thymosin β 4 reduces lethality and downmodulates inflammatory mediators in endotoxin induced septic shock. Int Immunopharmacol 3: 1225–1233.
[9]
Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivasta D (2004) Thymosin beta 4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432: 466–472.
[10]
Hsiao HL, Wang WS, Chen PM, Su Y (2006) Overexpression of thymosin beta-4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via down-regulating Fas and up-regulating Survivin expression, respectively. Carcinogenesis 27: 936–944.
[11]
Qiu P, Wheater MK, Qiu Y, Sosne G (2011) Thymosin beta4 inhibits TNF-alpha-induced NF-kappa B activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J 25: 1815–26.
[12]
David C, Nabila T, Christian A, Janet A (2010) Thymosin β4: structure, function, and biological properties supporting current and future clinical applications. Ann. NY Acad Sci 1194: 179–189.
[13]
Yu FX, Lin SC, Morrison-Bogorad M, Yin HL (1994) Effects of thymosin β4 and thymosin β10 on actin structures in living cells. Cell Motil Cytoskeleton 27: 13–25.
[14]
Watts JD, Cary PD, Sautiere P, Crane-Robinson C (1990) Thymosins: both nuclear and cytoplasmic proteins. Eur J Biochem 192: 643–651.
[15]
Huff T, Rosorius O, Otto AM, Müller CSG, Ballweber E, et al. (2004) Nuclear localization of the G-actin sequestering peptide thymosin β4. Journal of Cell Science 117: 5333–5343.
[16]
McCormack SA, Ray RM, Blanner PM, Johnson LR (1999) Polyamine depletion alters the relationship of F-actin, G-actin, and thymosin β4 in migrating IEC-6 cells. Am J Physiol 276: C459–C468.
[17]
Zoubek RE, Hannappel E (2007) Subcellular distribution of thymosin beta4. Ann N Y Acad Sci 1112: 442–450.
[18]
Nemolato S, Van Eyken P, Cabras T, Cau F, Fanari MU, et al. (2011) Expression pattern of thymosin beta 4 in the adult human liver. Eur J Histochem 55: 131–135.
[19]
Kang S, Song J, Kang H, Kim S, Lee Y, et al. (2003) Insulin can block apoptosis by decreasing oxidative stress via phosphatidylinositol 3-kinase- and extracellular signal-regulated protein kinase-dependent signaling pathways in HepG2 cells. Eur J Endocrinol 148: 147–155.
[20]
Schamberger CJ, Gerner C, Cerni C (2005) Caspase-9 plays a marginal role in serum starvation-induced apoptosis. Exp Cell Res 302: 115–128.
[21]
Zhuge J, Cederbaum AI (2006) Serum deprivation-induced HepG2 cell death is potentiated by CYP2E1. Free Radic Biol Med 40: 63–74.
[22]
Bai J, Cederbaum AI (2006) Cycloheximide protects HepG2 cells from serum withdrawal induced apoptosis by decreasing p53 and phosphorylated p53 levels. J Pharmacol and Experimental Therap 319: 1435–1443.
[23]
Galan JA, Paris LL, Zhang H, Adler J, Geahlen RL, et al. (2011) Proteomic Studies of Syk-Interacting Proteins Using a Novel Amine-Specific Isotope Tag and GFP Nanotrap. J Am Soc Mass Spectrom 22: 319Y328.
[24]
Inzitari R, Cabras T, Pisano E, Fanali C, Manconi B, et al. (2009) HPLC-ESI-MS analysis of oral human fluids reveals that gingival crevicular fluid is the main source of oral thymosins beta(4) and beta(10). J Sep Sci 32: 57–63.
[25]
Zhang Z, Marshall AG (1998) A universal algorithm for fast and automated charge state deconvolution of electrospray mass-to-charge ratio spectra. J Am Soc Mass Spectrom 9: 225–233.
[26]
Ong SE, Mann M (2005) Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 1: 252–262.
[27]
Hannappel E, Leibold W (1985) Biosynthesis rates and content of thymosin β4 in cell lines. Arch Biochem Biophys 240: 236–241.
[28]
Su HQ, Yin HL (2007) The beta-thymosin enigma. Ann N Y Acad Sci 1112: 45–55.
[29]
Nemolato S, Restivo A, Cabras T, Coni P, Zorcolo L, et al. (2012) Thymosin β4 in colorectal cancer is localized predominantly at the invasion front in tumor cells undergoing epithelial mesenchymal transition. Cancer Biol Ther 13: 191–197.
[30]
Wodnar-Filipowicz A, Gubler U, Furuichi Y, Richardson M, Horecker BL (1984) Cloning and sequence analysis of cDNA for rat spleen thymosin beta 4. Proc Natl Acad Sci USA 81: 2295–2297.
[31]
Brieger A, Plotz G, Zeuzem S, Trojan J (2007) Thymosin beta 4 expression and nuclear transport are regulated by hMLH1. Biochem Biophys Res Commun 364: 731–736.
[32]
Gettemans J, Van Impe K, Delanote V, Hubert T, Vandekerckhove J, et al. (2005) Nuclear actin-binding proteins as modulators of gene transcription. Traffic 6: 847–857.
